6. Expansion of the validation of Illumina MethylationEPIC BeadChip for medulloblastoma (MB) subgrouping and copy number analysis across institutions and results from the initial 47 clinical cases

Background: MB is a common pediatric brain tumor traditionally risk-stratified using age, histology, metastasis and extent of resection. Gene expression studies show four major subgroups: WNT, SHH, Group 3 and Group 4. Profiling using the Illumina Methylation450 BeadChip helps subgroup these tumors. Additional studies show these subgroups have characteristic copy number changes (CNC). We expanded our initial validation cohort for MB subgrouping and copy number analyses (CNA).

Source: Cancer Genetics and Cytogenetics - March 31, 2019 Category: Genetics & Stem Cells Authors: Teresa Smolarek, Brenna Hott, Ralph Salloum, Christine Fuller, Vijay Ramaswamy, Michael Taylor, Maryam Fouladi, Lisa Dyer, Rachid Drissi Source Type: research